Skip to main content

TNF vs TCZ in Takayasu's Arteritis

Dr. Michael Putman | Abstract 1124 | ACR 2026

Transcription

Hi everyone, it's Mike Putman. I'm a rheumatologist at the Medical College of Wisconsin and I'm here to talk about abstract 0169, the comparative effectiveness of tocilizumab and TNF inhibitors in Takayasu arteritis. Kind of rolls off the tongue, you know, Toci versus TNF and TAK.

So, you know, this is a really interesting study. The guidelines and the recommended first-line therapy for Takayasu arteritis is a TNF inhibitor. And I've always liked TNF inhibitors in this disease. But, you know, I think a little part of us always thinks large vessel vasculitis, what about tocilizumab? There was a large randomized control trial that investigated this, the TACT study. It was technically a failed study, but the P value was like 0.0596 or something. If you squint real tight, you sure see a lot of signs of benefit. I think in practice, a lot of us do use tocilizumab in some situations.

So, this study is a really cool observational cohort from the NIH. It's one of my favorite vasculitis groups and they had 121 people on TNFs and 30 people on Toci who had Takayasu arteritis, and what they said is, you know, what does remission look like and what does crossover look like in this group.

So what they saw — the first headline that I thought was interesting is that among people who switch classes, so either going TNF to Toci or Toci to a TNF, response rate was 94%. So it looks like class switching after one doesn't work is probably a good idea. Can we predict that? Not really. The only thing that really sort of shifted you towards Toci or a TNF being more effective upfront was age. And this actually goes the way you'd expect — older folks did better on Toci initially, or a little more. And then people who are younger, maybe a TNF would be a better choice. Remember, this is all Takayasu, so all of these people are, you know, under 40, kind of in the Takayasu range.

The next really interesting question that I thought was, you know, what would predict response among either of them? And there are the usual things you look for — elevated inflammatory markers, PET scans, things like that. None of that was actually predictive. It looked like the really the only major thing to take home was that either one would be great once you switched, and that age is the main predictor that would point you in one direction or the other.

My favorite takehome from this though is that I think either one would be a reasonable option in the right situation for the right patient. So very cool study. It was recently published in Arthritis Care and Research. So check it out. Thanks so much for having me.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×